Cargando…

Bringing enzymes to the proximity party

Enzymes are used to treat a wide variety of human diseases, including lysosomal storage disorders, clotting disorders, and cancers. While enzyme therapeutics catalyze highly specific reactions, they often suffer from a lack of cellular or tissue selectivity. Targeting an enzyme to specific disease-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tender, Gabrielle S., Bertozzi, Carolyn R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685825/
https://www.ncbi.nlm.nih.gov/pubmed/38033727
http://dx.doi.org/10.1039/d3cb00084b
_version_ 1785151708605710336
author Tender, Gabrielle S.
Bertozzi, Carolyn R.
author_facet Tender, Gabrielle S.
Bertozzi, Carolyn R.
author_sort Tender, Gabrielle S.
collection PubMed
description Enzymes are used to treat a wide variety of human diseases, including lysosomal storage disorders, clotting disorders, and cancers. While enzyme therapeutics catalyze highly specific reactions, they often suffer from a lack of cellular or tissue selectivity. Targeting an enzyme to specific disease-driving cells and tissues can mitigate off-target toxicities and provide novel therapeutic avenues to treat otherwise intractable diseases. Targeted enzymes have been used to treat cancer, in which the enzyme is either carefully selected or engineered to reduce on-target off-tumor toxicity, or to treat lysosomal storage disorders in cell types that are not addressed by standard enzyme replacement therapies. In this review, we discuss the different targeted enzyme modalities and comment on the future of these approaches.
format Online
Article
Text
id pubmed-10685825
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-106858252023-11-30 Bringing enzymes to the proximity party Tender, Gabrielle S. Bertozzi, Carolyn R. RSC Chem Biol Chemistry Enzymes are used to treat a wide variety of human diseases, including lysosomal storage disorders, clotting disorders, and cancers. While enzyme therapeutics catalyze highly specific reactions, they often suffer from a lack of cellular or tissue selectivity. Targeting an enzyme to specific disease-driving cells and tissues can mitigate off-target toxicities and provide novel therapeutic avenues to treat otherwise intractable diseases. Targeted enzymes have been used to treat cancer, in which the enzyme is either carefully selected or engineered to reduce on-target off-tumor toxicity, or to treat lysosomal storage disorders in cell types that are not addressed by standard enzyme replacement therapies. In this review, we discuss the different targeted enzyme modalities and comment on the future of these approaches. RSC 2023-09-29 /pmc/articles/PMC10685825/ /pubmed/38033727 http://dx.doi.org/10.1039/d3cb00084b Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Tender, Gabrielle S.
Bertozzi, Carolyn R.
Bringing enzymes to the proximity party
title Bringing enzymes to the proximity party
title_full Bringing enzymes to the proximity party
title_fullStr Bringing enzymes to the proximity party
title_full_unstemmed Bringing enzymes to the proximity party
title_short Bringing enzymes to the proximity party
title_sort bringing enzymes to the proximity party
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685825/
https://www.ncbi.nlm.nih.gov/pubmed/38033727
http://dx.doi.org/10.1039/d3cb00084b
work_keys_str_mv AT tendergabrielles bringingenzymestotheproximityparty
AT bertozzicarolynr bringingenzymestotheproximityparty